BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vandyck K, Deval J. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection. Curr Opin Virol 2021;49:36-40. [PMID: 34029993 DOI: 10.1016/j.coviro.2021.04.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Tian L, Pang Z, Li M, Lou F, An X, Zhu S, Song L, Tong Y, Fan H, Fan J. Molnupiravir and Its Antiviral Activity Against COVID-19. Front Immunol 2022;13:855496. [DOI: 10.3389/fimmu.2022.855496] [Reference Citation Analysis]
2 Costanzi E, Kuzikov M, Esposito F, Albani S, Demitri N, Giabbai B, Camasta M, Tramontano E, Rossetti G, Zaliani A, Storici P. Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L. Int J Mol Sci 2021;22:11779. [PMID: 34769210 DOI: 10.3390/ijms222111779] [Reference Citation Analysis]
3 Alvarado YJ, Olivarez Y, Lossada C, Vera-villalobos J, Paz JL, Vera E, Loroño M, Vivas A, Torres FJ, Jeffreys LN, Hurtado-león ML, González-paz L. Interaction of the New Inhibitor Paxlovid (PF-07321332) and Ivermectin With the Monomer of the Main Protease SARS-CoV-2: A Volumetric Study Based on Molecular Dynamics, Elastic Networks, Classical Thermodynamics and SPT. Computational Biology and Chemistry 2022. [DOI: 10.1016/j.compbiolchem.2022.107692] [Reference Citation Analysis]
4 Ho WS, Zhang R, Tan YL, Chai CLL. COVID-19 and The Promise of Small Molecule Therapeutics: Are There Lessons to be Learnt? Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106201] [Reference Citation Analysis]
5 Hu S, Jiang S, Qi X, Bai R, Ye XY, Xie T. Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review. Drug Dev Res 2021. [PMID: 34762760 DOI: 10.1002/ddr.21895] [Reference Citation Analysis]
6 Sabnis RW. Novel Compounds for Preventing SARS-CoV-2 Viral Replication and Treating COVID-19. ACS Med Chem Lett 2021;12:1887-8. [PMID: 34917247 DOI: 10.1021/acsmedchemlett.1c00610] [Reference Citation Analysis]
7 Ullrich S, Sasi VM, Mahawaththa MC, Ekanayake KB, Morewood R, George J, Shuttleworth L, Zhang X, Whitefield C, Otting G, Jackson C, Nitsche C. Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors. Bioorg Med Chem Lett 2021;50:128333. [PMID: 34418570 DOI: 10.1016/j.bmcl.2021.128333] [Reference Citation Analysis]
8 Hardenbrook NJ, Zhang P. A structural view of the SARS-CoV-2 virus and its assembly. Curr Opin Virol 2021;52:123-34. [PMID: 34915287 DOI: 10.1016/j.coviro.2021.11.011] [Reference Citation Analysis]
9 White JM, Schiffer JT, Bender Ignacio RA, Xu S, Kainov D, Ianevski A, Aittokallio T, Frieman M, Olinger GG, Polyak SJ, Prasad VR. Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. mBio 2021;12:e03347-21. [DOI: 10.1128/mbio.03347-21] [Reference Citation Analysis]
10 Muhtar E, Wang M, Zhu H. In silico discovery of SARS-CoV-2 main protease inhibitors from the carboline and quinoline database. Future Virol 2021. [PMID: 34306166 DOI: 10.2217/fvl-2021-0099] [Reference Citation Analysis]
11 Basu D, Chavda VP, Mehta AA. Therapeutics for COVID-19 and post COVID-19 complications: An update. Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100086] [Reference Citation Analysis]
12 Majerová T, Novotný P. Precursors of Viral Proteases as Distinct Drug Targets. Viruses 2021;13:1981. [PMID: 34696411 DOI: 10.3390/v13101981] [Reference Citation Analysis]
13 Plemper RK. Editorial overview: Special issue on antiviral strategies in Current Opinion in Virology. Curr Opin Virol 2021;50:95-6. [PMID: 34419858 DOI: 10.1016/j.coviro.2021.07.008] [Reference Citation Analysis]
14 Paul A, Sarkar A, Saha S, Maji A, Janah P, Kumar Maity T. Synthetic and computational efforts towards the development of peptidomimetics and small-molecule SARS-CoV 3CLpro inhibitors. Bioorg Med Chem 2021;:116301. [PMID: 34332853 DOI: 10.1016/j.bmc.2021.116301] [Reference Citation Analysis]
15 Yoo JH. Antivirals for Coexistence with COVID-19: Brief Review for General Physicians. J Korean Med Sci 2021;36:e298. [PMID: 34725982 DOI: 10.3346/jkms.2021.36.e298] [Reference Citation Analysis]
16 Hamdy R, Fayed B, Mostafa A, Shama NMA, Mahmoud SH, Mehta CH, Nayak Y, M Soliman SS. Iterated Virtual Screening-Assisted Antiviral and Enzyme Inhibition Assays Reveal the Discovery of Novel Promising Anti-SARS-CoV-2 with Dual Activity. Int J Mol Sci 2021;22:9057. [PMID: 34445763 DOI: 10.3390/ijms22169057] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Hijikata A, Shionyu C, Nakae S, Shionyu M, Ota M, Kanaya S, Shirai T. Current status of structure-based drug repurposing against COVID-19 by targeting SARS-CoV-2 proteins. Biophys Physicobiol 2021;18:226-40. [PMID: 34745807 DOI: 10.2142/biophysico.bppb-v18.025] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zakharova MY, Kuznetsova AA, Uvarova VI, Fomina AD, Kozlovskaya LI, Kaliberda EN, Kurbatskaia IN, Smirnov IV, Bulygin AA, Knorre VD, Fedorova OS, Varnek A, Osolodkin DI, Ishmukhametov AA, Egorov AM, Gabibov AG, Kuznetsov NA. Pre-Steady-State Kinetics of the SARS-CoV-2 Main Protease as a Powerful Tool for Antiviral Drug Discovery. Front Pharmacol 2021;12:773198. [PMID: 34938188 DOI: 10.3389/fphar.2021.773198] [Reference Citation Analysis]
19 Johansen-leete J, Ullrich S, Fry SE, Frkic R, Bedding MJ, Aggarwal A, Ashhurst AS, Ekanayake KB, Mahawaththa MC, Sasi VM, Luedtke S, Ford DJ, O'donoghue AJ, Passioura T, Larance M, Otting G, Turville S, Jackson CJ, Nitsche C, Payne RJ. Antiviral cyclic peptides targeting the main protease of SARS-CoV-2. Chem Sci . [DOI: 10.1039/d1sc06750h] [Reference Citation Analysis]
20 Antonopoulou I, Sapountzaki E, Rova U, Christakopoulos P. Inhibition of the main protease of SARS-CoV-2 (Mpro) by repurposing/designing drug-like substances and utilizing nature’s toolbox of bioactive compounds. Computational and Structural Biotechnology Journal 2022. [DOI: 10.1016/j.csbj.2022.03.009] [Reference Citation Analysis]
21 Nakayoshi T, Kato K, Kurimoto E, Oda A. Virtual Alanine Scan of the Main Protease Active Site in Severe Acute Respiratory Syndrome Coronavirus 2. Int J Mol Sci 2021;22:9837. [PMID: 34576002 DOI: 10.3390/ijms22189837] [Reference Citation Analysis]
22 Chia CSB, Xu W, Shuyi Ng P. A Patent Review on SARS Coronavirus Main Protease (3CLpro ) Inhibitors. ChemMedChem 2021. [PMID: 34651447 DOI: 10.1002/cmdc.202100576] [Reference Citation Analysis]
23 Tarnawski AS, Ahluwalia A. Endothelial cells and blood vessels are major targets for COVID-19-induced tissue injury and spreading to various organs. World J Gastroenterol 2022;28:275-89. [PMID: 35110950 DOI: 10.3748/wjg.v28.i3.275] [Reference Citation Analysis]
24 Bai B, Arutyunova E, Khan MB, Lu J, Joyce MA, Saffran HA, Shields JA, Kandadai AS, Belovodskiy A, Hena M, Vuong W, Lamer T, Young HS, Vederas JC, Tyrrell DL, Lemieux MJ, Nieman JA. Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors. RSC Med Chem 2021;12:1722-30. [PMID: 34778773 DOI: 10.1039/d1md00247c] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Zhao Y, Fang C, Zhang Q, Zhang R, Zhao X, Duan Y, Wang H, Zhu Y, Feng L, Zhao J, Shao M, Yang X, Zhang L, Peng C, Yang K, Ma D, Rao Z, Yang H. Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332. Protein Cell 2021. [PMID: 34687004 DOI: 10.1007/s13238-021-00883-2] [Reference Citation Analysis]
26 Hung Y, Lee J, Chiu C, Lee C, Tsai P, Hsu I, Ko W. Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark? Antibiotics 2022;11:220. [DOI: 10.3390/antibiotics11020220] [Reference Citation Analysis]
27 Lin Y, Zang R, Ma Y, Wang Z, Li L, Ding S, Zhang R, Wei Z, Yang J, Wang X. Xanthohumol Is a Potent Pan-Inhibitor of Coronaviruses Targeting Main Protease. Int J Mol Sci 2021;22:12134. [PMID: 34830015 DOI: 10.3390/ijms222212134] [Reference Citation Analysis]